Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer

Inclusion Criteria: * Women with histological diagnosis of invasive breast cancer requiring neoadjuvant chemotherapy * T2 tumour or above * WHO Performance status of 0,1 or 2 * Must consent to or have undergone a core biopsy for diagnosis of breast cancer AND consent to undergo an additional core biopsy prior to the second cycle of chemotherapy (Day 5 +/- Day 21) * Written informed consent Exclusion Criteria: * Previous chemotherapy or radiotherapy to treated breast * Evidence of metastatic disease or recurrent breast cancer or previous malignancy (some exceptions) * Calculated creatinine clearance \< 40mls/min * Prior treatment with bisphosphonates in last year or known contraindications to bisphosphonate therapy * Concurrent tamoxifen or aromatase inhibitor medication * Pregnant or lactating women * Cardiac dysfunction that precludes use of anthracycline chemotherapy * Unwilling to have extra interim biopsy